• Consensus Rating: Moderate Buy
  • Consensus Price Target: $3.83
  • Forecasted Upside: 109.47%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$1.83
▼ -0.01 (-0.54%)

This chart shows the closing price for CERS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Cerus Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CERS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CERS

Analyst Price Target is $3.83
▲ +109.47% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Cerus in the last 3 months. The average price target is $3.83, with a high forecast of $5.00 and a low forecast of $2.50. The average price target represents a 109.47% upside from the last price of $1.83.

This chart shows the closing price for CERS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 3 polled investment analysts is to moderate buy stock in Cerus. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/21/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/21/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/19/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/17/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/16/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/15/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/14/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/13/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/3/2024Cantor FitzgeraldBoost TargetOverweight ➝ Overweight$3.00 ➝ $4.00Low
4/12/2024Craig HallumInitiated CoverageBuy$5.00Low
3/7/2024StephensReiterated RatingEqual Weight ➝ Equal Weight$2.50Low
3/6/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$3.00Low
11/8/2023Cantor FitzgeraldReiterated RatingOverweight$9.00 ➝ $3.00Low
7/10/2023Cantor FitzgeraldReiterated RatingOverweightLow
1/20/2023BTIG ResearchDowngradeBuy ➝ NeutralLow
1/17/2023StephensDowngradeOverweight ➝ Equal Weight$3.75Low
12/5/2022Cantor FitzgeraldReiterated RatingOverweightLow
11/15/2022BTIG ResearchLower Target$6.00N/A
6/15/2020Cantor FitzgeraldInitiated CoverageBuy$9.00High
6/8/2020Cantor FitzgeraldReiterated RatingOverweightHigh
5/27/2020Stifel NicolausBoost TargetBuy$7.00 ➝ $8.00Low
4/16/2020StephensLower TargetOverweight$7.50 ➝ $6.50Low
2/26/2020BTIG ResearchInitiated CoverageBuy$7.00High
11/13/2019BTIG ResearchUpgradeNeutral ➝ Buy$7.00Medium
8/27/2019Stifel NicolausInitiated CoverageBuy$7.00 ➝ $7.00Medium
8/22/2019StephensInitiated CoverageOverweight$8.00High
(Data available from 6/13/2019 forward)

News Sentiment Rating

1.34 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
11/15/2023
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/15/2023
  • 1 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
1/14/2024
  • 3 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/13/2024
  • 8 very positive mentions
  • 17 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
3/14/2024
  • 12 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/13/2024
  • 4 very positive mentions
  • 7 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
5/13/2024
  • 4 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/12/2024

Current Sentiment

  • 4 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.
Cerus logo
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was incorporated in 1991 and is headquartered in Concord, California.
Read More

Today's Range

Now: $1.83
Low: $1.82
High: $1.86

50 Day Range

MA: $1.80
Low: $1.62
High: $2.04

52 Week Range

Now: $1.83
Low: $1.21
High: $3.08

Volume

23,912 shs

Average Volume

1,338,093 shs

Market Capitalization

$338.35 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.26

Frequently Asked Questions

What sell-side analysts currently cover shares of Cerus?

The following Wall Street analysts have issued research reports on Cerus in the last year: Cantor Fitzgerald, Craig Hallum, Stephens, and StockNews.com.
View the latest analyst ratings for CERS.

What is the current price target for Cerus?

3 Wall Street analysts have set twelve-month price targets for Cerus in the last year. Their average twelve-month price target is $3.83, suggesting a possible upside of 108.3%. Craig Hallum has the highest price target set, predicting CERS will reach $5.00 in the next twelve months. Stephens has the lowest price target set, forecasting a price of $2.50 for Cerus in the next year.
View the latest price targets for CERS.

What is the current consensus analyst rating for Cerus?

Cerus currently has 1 hold rating and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for CERS.

What other companies compete with Cerus?

How do I contact Cerus' investor relations team?

Cerus' physical mailing address is 1220 CONCORD AVENUE SUITE 600, CONCORD CA, 94520. The biotechnology company's listed phone number is (925) 288-6000 and its investor relations email address is [email protected]. The official website for Cerus is www.cerus.com. Learn More about contacing Cerus investor relations.